Gabapentin :: Multiple pharmacies comparison.

NEW YORK — The combination of gabapentin with an antiviral and analgesics was more effective than were those drugs without gabapentin for reducing pain in patients with herpes zoster, suggesting that it may prevent postherpetic neuralgia in these patients, said Dr. Stephen Tyring, who presented as-yet-unpublished findings at the American Academy of Dermatology’s Academy 2007 meeting.
Dr. Tyring, professor of dermatology, microbiology/molecular …

MIAMI — Ivax Corp. is marketing generic Neurontin (gabapentin) in 100-, 300- and 400-mg tablets.
The drug, indicated for the treatment of partial seizures, received approval from the Food and Drug Administration earlier this year as the first generic gabapentin on the market.
Besides having 180-day exclusivity for the tablets in those three strengths, Ivax has tentative approval from the FDA for a capsule version in those dosages and plans to begin selling the capsules upo…

M2 PRESSWIRE-14 June 2007-ExplorationInvestor: Depomed Begins Dosing Patients in Phase 2 Trial For Gabapentin GR to Treat Menopausal Hot Flashes(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:14062007 Exploration Investor strives to provide…

Gabapentin tablets (600 mg and 800 mg) are approved for adjunctive therapy in the treatment of partial seizures of epilepsy and postherpetic neuralgia. This product is the generic equivalent of Neurontin. For more information, contact Alpharma Inc. at 800-638-9096 or…

Apotex Inc (Weston, Ontario, Canada), has introduced its oral gabapentin generic. In prescription strengths of 600 mg and 800 mg, gabapentin is approved for use as adjunctive therapy for patients with epilepsy and for the treatment of postherpetic neuralgia.

Related Results

GabapentinGabapentin withdrawalIVAX Launches Gabapentin CapsulesBattle commences on generic…

MENLO PARK, Calif. — Depomed, Inc. (Nasdaq:DEPO) announced today that results from two studies of Gabapentin GR support the ability of its improved, extended release formulation to achieve dose-proportional absorption of the pain drug, gabapentin. Gabapentin GR extended release tablets are in development for the treatment of postherpetic neuralgia (PHN), a long lasting pain condition caused by nerve dam…

In mid-January, the FDA was close to a decision on pending applications for a generic form of Neurontin (gabapentin), based on a federal court’s complicated patent decision.The Washington, D.C., federal court directed the FDA to accept the ANDA submitted by Purepac, which is eligible for 180 days of exclusivity as the first sponsor. TorPh…

M2 PRESSWIRE-25 April 2007-Biotech News: Shareholders alert for Xenoport, Inc.(C)1994-2007 M2 COMMUNICATIONS LTD RDATE:25042007 Shareholders alert for Xenoport, Inc. (NASDAQ:XNPT) Xenoport, Inc. operates as a biopharmaceutical company in the United States. It focuses on developing a portfolio of internally discovered product candidates that utilize the body’s natural nutri…

Depomed, Inc. (NASDAQ:DEPO) announced today that it has received a
Notice of Allowance from the U.S. Patent and Trademark Office for U.S.
patent application number 10/280,309.

Paul B. Simboli, Depomed’s director of Intellectual Property,
noted that the patent contains claims directed to methods for treating
neuropathic pain and claims related to methods for delivering
compounds via specific dosage form technologies.

…

WASHINGTON INSIDER

Most Popular
3 Questions No Job Seeker Ever Wants To Be Asked?
Public Speaking: 7 Secrets Of Great Public Speakers
13 Job Interview Mistakes To Avoid
5 Regular Mistakes In Public Speaking
10 Jobs That Pay $30 An Hour

The Division of Drug Marketing, Advertising, and Communications (DDMAC) has ordered Pfizer Inc to discontinue use of Neurontin (gabapentin) promoti…